Europe Point Of Care Poc Drug Abuse Testing Market
Market Size in USD Billion
CAGR :
% 
 Forecast Period |
2024 –2031 |
 Market Size (Base Year) |
USD 392.45 Million |
 Market Size (Forecast Year) |
USD 543.00 Million |
 CAGR |
% |
| Major Markets Players |
Europe Point-of-Care (POC) Drug Abuse Testing Market, By Drug Type (Amphetamines, Opiates, Cannabinoids, Cocaine, Barbiturates, Benzodiazepines, Methadone, Phencyclidine, Tricyclic Antidepressants, and Others), Products (Devices and Consumables and Accessories), Prescription (Over the Counter Testing and Prescription-Based Testing), Sample Type (Urine, Saliva, Blood, Hair, Breath, and Others), Testing Type (Random Testing, Post-Incident Testing, and Abstinence Testing), Application (Medical Screening, Workplace Screening, Law Enforcement and Criminal Justice, Pain Management, Substance Abuse Treatment and Rehabilitation, Parental or Home Drug Testing, Sports and Athletics Testing, Drug Screening in Schools and Educational Institutions, and Others), End User (Healthcare Facilities, Employers, Government Institutes, and Others), Distribution Channel (Direct Tender, Retails Sales, and Others) - Industry Trends and Forecast to 2031.
Europe Point-of-Care (POC) Drug Abuse Testing Market Analysis and Size
The market is driven by increasing awareness and emphasis on drug abuse prevention and management, along with the growing need for quick and accurate drug testing in diverse environments. Key factors fueling market growth include rising drug abuse rates, stringent regulatory requirements for drug testing in workplaces, and advancements in POC testing technologies that offer enhanced accuracy and user convenience. Additionally, the growing prevalence of substance abuse disorders across different demographics contributes to the demand for effective and accessible drug testing solutions.
The Europe Point-of-Care (POC) drug abuse testing market encompasses a range of diagnostic technologies and solutions designed to detect the presence of illicit substances or controlled drugs in an individual’s system at the location of care, rather than in a traditional laboratory setting. These tests provide rapid, on-the-spot results, which are crucial for timely decision-making and intervention in various settings such as medical facilities, emergency rooms, workplaces, and even in home settings. The market includes devices and testing kits for detecting drugs in urine, saliva, blood, and other biological samples.
Data Bridge Market Research analyzes that the Europe Point-of-Care (POC) drug abuse testing market is expected to reach USD 543.00 million by 2031 from USD 392.45 million in 2023, growing with a CAGR of 4.3% in the forecast period of 2024 to 2031.
|
Report Metric |
Details |
|
Forecast Period |
2024 to 2031 |
|
Base Year |
2023 |
|
Historic Years |
2022 (Customizable 2016-2021) |
|
Quantitative Units |
Revenue in USD Million |
|
Segments Covered |
Drug Type (Amphetamines, Opiates, Cannabinoids, Cocaine, Barbiturates, Benzodiazepines, Methadone, Phencyclidine, Tricyclic Antidepressants, and Others), Products (Devices and Consumables and Accessories), Prescription (Over the Counter Testing and Prescription-Based Testing), Sample Type (Urine, Saliva, Blood, Hair, Breath, and Others), Testing Type (Random Testing, Post-Incident Testing, and Abstinence Testing), Application (Medical Screening, Workplace Screening, Law Enforcement and Criminal Justice, Pain Management, Substance Abuse Treatment and Rehabilitation, Parental or Home Drug Testing, Sports and Athletics Testing, Drug Screening in Schools and Educational Institutions, and Others), End User (Healthcare Facilities, Employers, Government Institutes, and Others), Distribution Channel (Direct Tender, Retails Sales, and Others) |
|
Countries Covered |
Germany, France, U.K., Italy, Spain, Russia, Netherlands, Switzerland, Turkey, Belgium, Norway, Austria, Hungary, Ireland, Kazakhstan, Belarus, Lithuania, Uzbekistan, Azerbaijan, Armenia, Moldova, Tajikistan, Kyrgyzstan, Poland, Rest of Europe |
|
Market Players Covered |
Abbott Laboratories, Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc., F.Hoffman-La Roche Ltd., Siemens Healthineers AG, MP Biomedicals., Beijing Hotgen Biotechn Co., LTD., Assure Tech (Hangzhou) co., ltd., Accubio Tech Co., ltd. Premier biotech,inc., Wondfo and, among others |
Market Definition
Point-of-Care (PoC) drug abuse testing refers to rapid screening methods used to detect the presence of drugs or their metabolites in a person's system at the site of care, such as clinics or emergency rooms. These tests provide quick results, enabling timely decision-making for treatment or intervention. Typically involving urine, saliva, or blood samples, PoC testing is essential for monitoring substance use, ensuring patient safety, and facilitating access to appropriate support services.
Europe Point-of-Care (POC) Drug Abuse Testing Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail as below:
Drivers
- Rising Incidence of Drug Abuse
Drug abuse involving opiates, cannabinoids, and amphetamines has been growing regionally, creating a public health crisis that requires immediate and scalable solutions. Healthcare providers, law enforcement agencies, and employers are increasingly relying on POC drug testing as it offers rapid, accurate, and on-site detection, which is critical in managing the consequences of drug abuse.
In healthcare, the need for quick detection of drug abuse is essential to offer timely interventions, especially in emergency cases or rehabilitation centers. In law enforcement, the ability to test individuals on-site accelerates decision-making and enhances efforts to curb drug-related crimes. Similarly, workplaces are adopting POC drug testing to maintain a drug-free environment, reduce liability, and comply with safety regulations.
Technological advancements in POC testing devices further support the growing demand for rapid, reliable testing methods. These devices are becoming more portable, user-friendly, and capable of detecting a wide range of substances, making them ideal for use in non-laboratory settings.
For Instance,
- In January 2024, according to an article published by NCBI, Opioid Use Disorder (OUD) affects over 16 million people worldwide, including 2.1 million in the U.S., leading to more than 120,000 deaths regionally each year. The prevalence of opioid use and dependency is high, with up to 50% of long-term opioid users meeting OUD criteria. The rising incidence of opioid-related issues drives the need for effective drug testing solutions, thereby fuelling growth in the Europe Point-of-Care (POC) drug abuse testing market
- In August 2023, according to an article published by WHO, in 2019, approximately 600,000 deaths regionally were linked to drug use, with about 80% related to opioids. Of these, around 125,000 were due to opioid overdose, while non-fatal overdoses are significantly more common. The rise in opioid overdoses is attributed to increased opioid availability for chronic pain management and the presence of potent opioids on the illicit market. In the USA, drug overdose deaths totaled 70,630 in 2019, with synthetic opioids involved in about half of these cases.
Growth in Home and Parental Drug Testing Kits
The growing demand for easy-to-use, over-the-counter drug testing kits for home use reflects a strong consumer preference for privacy and convenience in monitoring substance use. Parents are increasingly adopting these kits to detect and prevent substance abuse among teenagers, while individuals are opting for self-testing options for personal reasons.
Technological advancements have led to the creation of more accurate, reliable, and user-friendly drug testing products, enabling consumers to perform tests privately at home without professional assistance. This convenience reduces the stigma associated with drug testing, fostering wider adoption of these solutions. Home testing kits are now more sensitive and capable of detecting a broad range of drugs, providing results that are comparable to those from laboratory tests.
Increased awareness of substance abuse and the easy availability of these kits through pharmacies and online platforms are contributing to market growth. The trend is further supported by a growing preference for non-invasive sample collection methods, such as saliva or urine tests, which are simple to use at home.
For instance,
- In November 2023, according to an article published by DNA Forensics Laboratory Pvt. Ltd., in recent years, at-home drug testing kits have become increasingly popular due to their convenience and ease of access. These kits enable individuals to conduct drug tests privately at home, typically including test strips or collection devices along with clear instructions for sample collection and result interpretation. This trend towards home testing highlights the "growth in home and parental drug testing kits" and drives the demand for such products. The growing preference for private and convenient drug testing solutions propels the expansion of the Europe Point-of-Care (POC) drug abuse testing market.
In conclusion, the rising demand for home and parental drug testing kits is driving significant growth in the POC drug abuse testing market by offering consumers private, convenient, and reliable options for substance abuse monitoring, fueling expansion in this segment.
Opportunity
- Growing Awareness and the Campaign for Drug Testing
The increasing awareness surrounding the dangers of drug abuse, coupled with robust public health campaigns and government support, presents a significant opportunity for growth in the Europe Point-of-Care (POC) drug abuse testing market. As society becomes more cognizant of the detrimental impacts of substance abuse, there is a growing demand for accessible and effective testing solutions. Public health campaigns, often spearheaded by governmental and non-governmental organizations, play a crucial role in educating communities about the importance of early detection and intervention. These initiatives not only amplify the visibility of drug abuse issues but also advocate for the use of point-of-care testing as a preventive measure. Furthermore, government support through funding and policy-making enhances the accessibility of POC drug testing solutions by promoting regulatory frameworks that facilitate the adoption of these technologies in various settings, including workplaces, schools, and public health programs. The combination of heightened awareness and strategic support fosters an environment conducive to market expansion, driving innovation and increasing the availability of advanced testing solutions to address the evolving needs of society.
- In December 2023, according to the article published by the Greater London Authority, UK government allocated USD 1.54 million to this mission, focusing on testing for 14 different drugs with the rising awareness and proactive government initiatives in the UK have led to the implementation of random mandatory drug testing for individuals released from prison, aiming to reduce crime rates. This move underscores the nation's commitment to tackling substance abuse and its impact on criminal behavior, reflecting broader efforts to enhance public safety and well-being.
- In July 2021, according to the article published by Commonwealth of Australia and the Department of Health and Aged Care, the Australian government launched the National Ice Action Strategy, which included significant investments to enhance Point-of-Care (POC) drug abuse testing. This initiative aimed to curb the growing use of methamphetamines, commonly known as "ice," by providing law enforcement and healthcare providers with more accessible and accurate drug testing tools. The strategy also focused on expanding the availability of POC testing in remote and rural areas, ensuring that communities across the country could benefit from timely and effective drug detection and intervention measures.
Hence, the convergence of growing awareness, active public health campaigns, and strong government support is poised to significantly benefit the Europe Point-of-Care (POC) drug abuse testing market. This dynamic environment not only promotes the adoption of drug testing technologies but also encourages the development of more sophisticated and accessible solutions. As these factors continue, the future of POC drug abuse testing looks promising, with enhanced opportunities for innovation, broader market reach, and improved public health outcomes.
Restraint/Challenge
- High Costs Associated with the Testing
The complexity of developing reliable and accurate POC drug abuse tests often requires advanced technology, specialized materials, and rigorous validation processes, all of which contribute to elevated production costs. These costs are further compounded by stringent regulatory requirements, as ensuring compliance with international standards demands extensive testing, quality control, and documentation, adding to the overall expense. Additionally, the need for consistent research and development to keep pace with emerging drug abuse patterns and to enhance the sensitivity and specificity of these tests drives up the costs even more. For healthcare providers, the high upfront investment required to integrate these testing solutions into their practices can be prohibitive, particularly for smaller clinics or organizations with limited budgets. This financial burden can deter the adoption of POC drug abuse testing despite its potential benefits in terms of speed and convenience. The situation is exacerbated in low- and middle-income countries, where healthcare budgets are already strained, and the added cost of POC testing can be a barrier to implementation, limiting the market's expansion into these regions. Moreover, the high cost can lead to disparities in healthcare access, as only well-funded institutions may be able to afford these advanced testing methods, leaving vulnerable populations without adequate testing and care. This challenge is not only a financial one but also an ethical issue, as the inability to provide affordable testing solutions undermines the efforts to combat drug abuse on a broader scale.
For instance,
- In May 2023, according to an article published by the National Library of Medicine, POC testing was costlier performed on an individual basis when compared to traditional laboratory testing due to the single-use nature of most POCT devices, which adds to the overall expenses.
- In January 2024, according to an article published by Checkr., the cost of drug testing for comprehensive laboratory panels can exceed USD 500. Onsite tests typically range from USD 20 to USD 40, but the need for lab confirmation can drive prices up, starting at USD 50 and varying based on the test type and substances screened. High volumes of tests might reduce the average cost per test, but the overall expense can still be substantial.
Hence, the high cost of POC drug abuse testing creates significant barriers to its broader adoption, limiting accessibility, especially in resource-constrained regions. This financial challenge not only hampers market growth but also exacerbates healthcare inequalities, preventing many from receiving timely and effective drug abuse testing, and is expected to act as a challenge for market growth in the future.
Recent Developments
- In August 2024, Abbott announced a Europe partnership with Medtronic on August 7, 2024, to integrate Abbott's advanced FreeStyle Libre Continuous Glucose Monitoring (CGM) technology with Medtronic's insulin delivery systems. This collaboration aimed to enable automatic insulin adjustments and improve diabetes management, benefiting over 11 million people worldwide. Financial terms were undisclosed
- In March 2024, Abbott extended its partnership with Real Madrid and the Real Madrid Foundation through the 2026-2027 season, continuing as their Europe health sciences and nutrition partner. Since 2021, Abbott provided over 25,000 hours of nutrition education and screened more than 3,000 children for malnutrition
- In August 2023, SSM Health, Siemens Healthineers partner to advance health equity and empower workforce development in underserved communities. The partnership with SSM Health benefits Siemens Healthineers by expanding its market presence, increasing visibility of its technology, fostering long-term growth, and enhancing its reputation in the healthcare sector
- In February 2024, Roche entered into collaboration agreement with PathAI to expand digital pathology capabilities for companion diagnostics. The collaboration provides Roche with PathAI’s advanced AI technology for improving companion diagnostics. It ensures exclusive, tailored solutions and accelerates algorithm development while allowing Roche to continue developing its own diagnostics
- In November 2023, Roche launched next-generation qPCR system to advance clinical needs in molecular diagnostics and address public health challenges. Roche’s next-generation qPCR system boosts its market position, meets clinical and public health needs, and opens new revenue opportunities while showcasing its commitment to innovation
Europe Point-of-Care (POC) drug abuse testing market Scope
The Europe Point-of-Care (POC) drug abuse testing market is segmented into eight notable segments based on drug type, products, prescription, sample type, testing type, application, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Drug Type
- Amphetamines
- Opiates
- Cannabinoids
- Cocaine
- Barbiturates
- Benzodiazepines
- Methadone
- Phencyclidine
- Tricyclic Antidepressants
- Others
On the basis of drug type, the market is segmented into amphetamines, cannabinoids, opiates, cocaine, benzodiazepines, barbiturates, phencyclidine, methadone, tricyclic antidepressants, and others.
Products
- Devices
- Consumables and Accessories
On the basis of products, the market is segmented into devices and consumables and accessories.
Prescription
- Over the Counter Testing
- Prescription-Based Testing
On the basis of prescription mode, the market is segmented into prescription-based testing, and over the counter testing.
Sample Type
- Urine
- Saliva
- Blood
- Hair
- Breath
- Others
On the basis of sample type, the market is segmented into urine, saliva, blood, hair, breath, and others.
Testing Type
- Random Testing
- Post-Incident Testing
- Abstinence Testing
On the basis of testing type, the market is segmented into random testing, post-incident testing, and abstinence testing.
Application
- Medical Screening
- Workplace Screening
- Law Enforcement and Criminal Justice
- Pain Management
- Substance Abuse Treatment and Rehabilitation
- Parental or Home Drug Testing
- Sports and Athletics Testing
- Drug Screening in Schools and Educational Institutions
- Others
On the basis of application, the market is segmented medical screening, workplace screening, law enforcement and criminal justice, pain management, substance abuse treatment and rehabilitation, parental or home drug testing, sports and athletics testing, drug screening in schools and educational institutions, and others.
End User
- Healthcare Facilities
- Employers
- Government Institutes
- Others
On the basis of end user, the market is segmented into healthcare facilities, employers, government institute, and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
On the basis of distribution channel, the market is segmented into direct tender, retails sales, and others.
Europe Point-of-Care (POC) Drug Abuse Testing Market Regional Analysis/Insights
Europe Point-of-Care (POC) drug abuse testing market is analyzed, and market size insights and trends are provided by based on drug type, products, prescription, sample type, testing type, application, end user, distribution channel as referenced above.
The countries covered in this market report are Germany, France, U.K., Italy, Spain, Russia, Netherlands, Switzerland, Turkey, Belgium, Norway, Austria, Hungary, Ireland, Kazakhstan, Belarus, Lithuania, Uzbekistan, Azerbaijan, Armenia, Moldova, Tajikistan, Kyrgyzstan, Poland, rest of Europe.
Germany is expected to dominate in the Europe market due to its advanced healthcare infrastructure, significant consumer demand for cold sore treatments, strong pharmaceutical industry, extensive research and development efforts, and well-established distribution networks, making it a hub for innovation and accessibility in cold sore management.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of regional brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Europe Point-of-Care (POC) Drug Abuse Testing Market Share Analysis
The Europe Point-of-Care (POC) drug abuse testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, regional presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the Europe Point-of-Care (POC) drug abuse testing market.
Some of the major players operating in the Europe Point-of-Care (POC) drug abuse testing market are Abbott Laboratories, Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc., F.Hoffman-La Roche Ltd., Siemens Healthineers AG, MP Biomedicals., Beijing Hotgen Biotechn Co., LTD., Assure Tech (Hangzhou) co., ltd., Accubio Tech Co., ltd. Premier biotech,inc., and Wondfo, among others
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS FIVE FORCES ANALYSIS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISING INCIDENCE OF DRUG ABUSE
5.1.2 GROWING EMPHASIS ON WORKPLACE SAFETY
5.1.3 GROWTH IN HOME AND PARENTAL DRUG TESTING KITS
5.1.4 RISING USE OF POC TESTING IN HEALTHCARE FACILITIES
5.2 RESTRAINTS
5.2.1 DATA SECURITY AND PRIVACY CONCERNS
5.2.2 LACK OF ACCURACY AND TECHNICAL CHALLENGES
5.3 OPPORTUNITIES
5.3.1 GROWING AWARENESS AND THE CAMPAIGN FOR DRUG TESTING
5.3.2 STRATEGIC INITIATION AND DECISION TAKEN BY THE MARKET PLAYERS
5.3.3 EXPANDING PRODUCT RANGE FOR POINT-OF-CARE DRUG ABUSE TESTING
5.4 CHALLENGES
5.4.1 LIMITED AWARENESS AND ACCEPTANCE
5.4.2 HIGH COSTS ASSOCIATED WITH THE TESTING
6 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE
6.1 OVERVIEW
6.2 AMPHETAMINES
6.3 OPIATES
6.4 CANNABINOIDS
6.5 COCAINE
6.6 BARBITURATES
6.7 BENZODIAZEPINES
6.8 METHADONE
6.9 PHENCYCLIDINE
6.1 TRICYCLIC ANTIDEPRESSANTS
6.11 OTHERS
7 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS
7.1 OVERVIEW
7.2 DEVICES
7.2.1 ANALYZER
7.2.1.1 IMMUNOASSAY ANALYZER
7.2.1.1.1 HIGH VOLUME
7.2.1.1.2 MID VOLUME
7.2.1.1.3 LOW VOLUME
7.2.1.2 BREATHALYZER
7.2.1.2.1 ELECTROCHEMICAL FUEL CELL BREATH ANALYZERS
7.2.1.2.2 INFRARED OPTICAL SENSOR BREATH ANALYZERS
7.2.1.2.3 SEMICONDUCTOR BREATH ANALYZERS
7.2.2 RAPID DEVICES
7.2.3 DRUG TESTING CASSETTE
7.2.4 DRUG TESTING CUPS
7.2.5 DIP CARDS/STRIPS
7.2.6 ORAL FLUID TESTING DEVICES
7.2.7 OTHERS
7.2.8 MODALITY
7.2.9 HANDHELD
7.2.10 MOBILE
7.2.11 MANUAL
7.2.12 AUTOMATED
7.3 CONSUMABLES AND ACCESSORIES
7.3.1 ASSAY KITS AND REAGENTS
7.3.2 PROBES
7.3.3 OTHERS
7.3.3.1 DAST-10
7.3.3.2 Plasma Protein Binding
7.3.3.3 Plasma and Serum Stability
7.3.3.4 Others
7.3.3.4.1 Multi-Panel Drug Test Kits
7.3.3.4.2 Single-Panel Drug Test Kits
8 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION
8.1 OVERVIEW
8.2 OVER THE COUNTER TESTING
8.3 PRESCRIPTION-BASED TESTING
9 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE
9.1 OVERVIEW
9.2 URINE
9.3 SALIVA
9.4 BLOOD
9.5 HAIR
9.6 BREATH
9.7 OTHERS
10 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE
10.1 OVERVIEW
10.2 RANDOM TESTING
10.3 POST-INCIDENT TESTING
10.4 ABSTINENCE TESTING
11 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 MEDICAL SCREENING
11.3 WORKPLACE SCREENING
11.4 LAW ENFORCEMENT AND CRIMINAL JUSTICE
11.5 PAIN MANAGEMENT
11.6 SUBSTANCE ABUSE TREATMENT AND REHABILITATION
11.7 PARENTAL OR HOME DRUG TESTING
11.8 SPORTS AND ATHLETICS TESTING
11.9 DRUG SCREENING IN SCHOOLS AND EDUCATIONAL INSTITUTIONS
11.1 OTHERS
12 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER
12.1 OVERVIEW
12.2 HEALTHCARE FACILITIES
12.2.1 HOSPITALS
12.2.2 EMERGENCY DEPARTMENT
12.2.3 CENTRAL LABS
12.2.4 CLINICS
12.2.5 POISON CONTROL CENTERS
12.2.6 OTHERS
12.3 EMPLOYERS
12.4 GOVERNMENT INSTITUTES
12.5 OTHERS
13 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
13.4 OTHERS
14 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION
14.1 EUROPE
14.1.1 GERMANY
14.1.2 U.K.
14.1.3 FRANCE
14.1.4 ITALY
14.1.5 SPAIN
14.1.6 TURKEY
14.1.7 RUSSIA
14.1.8 SWITZERLAND
14.1.9 NETHERLANDS
14.1.10 BELGIUM
14.1.11 AUSTRIA
14.1.12 NORWAY
14.1.13 POLAND
14.1.14 HUNGARY
14.1.15 IRELAND
14.1.16 KAZAKHSTAN
14.1.17 BELARUS
14.1.18 LITHUANIA
14.1.19 UZBEKISTAN
14.1.20 AZERBAIJAN
14.1.21 ARMENIA
14.1.22 MOLDOVA
14.1.23 TAJIKISTAN
14.1.24 KYRGYZSTAN
14.1.25 REST OF EUROPE
15 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: EUROPE
16 SWOT ANALYSIS
17 COMPANY PROFILES
17.1 ABBOTT LABORATORIES
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 SIEMENS HEALTHINEERS AG
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 QUEST DIAGNOSTICS INCORPORATED
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 THERMO FISHER SCIENTIFIC INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 F.HOFFMAN-LA ROCHE LTD.
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT UPDATES
17.5.6 RECENT UPDATES
17.6 ACCUBIOTECH CO., LTD.
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENT
17.7 ADVACARE PHARMA
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT UPDATES
17.8 AGILENT TECHNOLOGIES, INC
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT UPDATES
17.9 ASSURE TECH (HANGZHOU) CO., LTD.
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 BD
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 BEIJING HOTGEN BIOTECHN CO., LTD.
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENT
17.12 BIOEASY BIOTECHNOLOGY CO., LTD.,
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.13 BIO-RAD LABORATORIES, INC.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 CLIAWAIVED, INC.
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.15 DRUGSCAN
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 EGENS GROUP (NANTONG YISHI BIOTECHNOLOGY CO., LTD.)
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENT
17.17 HANGZHOU ALLTEST BIOTECH CO.,LTD
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 JOYSBIO (TIANJIN) BIOTECHNOLOGY CO., LTD
17.18.1 COMPANY SNAPSHOT
17.18.2 PRODUCT PORTFOLIO
17.18.3 RECENT UPDATES
17.19 LIFESIGN LLC.
17.19.1 COMPANY SNAPSHOT
17.19.2 PRODUCT PORTFOLIO
17.19.3 RECENT DEVELOPMENT
17.2 MERCK KGAA
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENTS
17.21 MP BIOMEDICALS
17.21.1 COMPANY SNAPSHOT
17.21.2 PRODUCT PORTFOLIO
17.21.3 RECENT DEVELOPMENT
17.22 PREMIER BIOTECH, INC.
17.22.1 COMPANY SNAPSHOT
17.22.2 PRODUCT PORTFOLIO
17.22.3 RECENT DEVELOPMENT
17.23 SYSMEX CORPORATION
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENTS
17.24 WONDFO
17.24.1 COMPANY SNAPSHOT
17.24.2 PRODUCT PORTFOLIO
17.24.3 RECENT DEVELOPMENT
17.25 XIAMEN BOSON BIOTECH CO., LTD.
17.25.1 COMPANY SNAPSHOT
17.25.2 PRODUCT PORTFOLIO
17.25.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
List of Table
TABLE 1 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 2 EUROPE AMPHETAMINES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 3 EUROPE OPIATES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 4 EUROPE CANNABINOIDS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 5 EUROPE COCAINE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 6 EUROPE BARBITURATES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 7 EUROPE BENZODIAZEPINES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 8 EUROPE METHADONE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 9 EUROPE PHENCYCLIDINE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 10 EUROPE TRICYCLIC ANTIDEPRESSANTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 11 EUROPE OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 12 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 13 EUROPE DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 14 EUROPE DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 15 EUROPE DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 16 EUROPE ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 17 EUROPE IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 18 EUROPE BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 19 EUROPE BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 20 EUROPE DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 21 EUROPE DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 22 EUROPE CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 23 EUROPE CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 24 EUROPE ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 25 EUROPE ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 26 EUROPE ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 27 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 28 EUROPE OVER THE COUNTER TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 29 EUROPE PRESCRIPTION-BASED TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 30 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 31 EUROPE URINE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 32 EUROPE SALIVA IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 33 EUROPE BLOOD IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 34 EUROPE HAIR IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 35 EUROPE BREATH IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 36 EUROPE OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 37 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 38 EUROPE RANDOM TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 39 EUROPE POST-INCIDENT TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 40 EUROPE ABSTINENCE TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 41 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 42 EUROPE MEDICAL SCREENING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 43 EUROPE WORKPLACE SCREENING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 44 EUROPE LAW ENFORCEMENT AND CRIMINAL JUSTICE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 45 EUROPE PAIN MANAGEMENT IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 46 EUROPE SUBSTANCE ABUSE TREATMENT AND REHABILITATION IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 47 EUROPE PARENTAL OR HOME DRUG TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 48 EUROPE SPORTS AND ATHLETICS TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 49 EUROPE DRUG SCREENING IN SCHOOLS AND EDUCATIONAL INSTITUTIONS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 50 EUROPE OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 51 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 52 EUROPE HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 53 EUROPE HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 54 EUROPE EMPLOYERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 55 EUROPE GOVERNMENT INSTITUTES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 56 EUROPE OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 57 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 58 EUROPE DIRECT TENDER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 59 EUROPE RETAIL SALES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 60 EUROPE OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 61 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 62 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 63 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 64 EUROPE DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 65 EUROPE DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 66 EUROPE DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 67 EUROPE ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 68 EUROPE IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 69 EUROPE BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 70 EUROPE BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 71 EUROPE BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 72 EUROPE DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 73 EUROPE DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 74 EUROPE CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 75 EUROPE ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 76 EUROPE ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 77 EUROPE ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 78 EUROPE ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 79 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 80 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 81 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 82 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 83 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 84 EUROPE HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 85 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 86 GERMANY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 87 GERMANY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 88 GERMANY DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 89 GERMANY DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 90 GERMANY DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 91 GERMANY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 92 GERMANY IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 93 GERMANY BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 94 GERMANY BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 95 GERMANY BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 96 GERMANY DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 97 GERMANY DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 98 GERMANY CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 99 GERMANY ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 100 GERMANY ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 101 GERMANY ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 102 GERMANY ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 103 GERMANY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 104 GERMANY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 105 GERMANY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 106 GERMANY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 107 GERMANY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 108 GERMANY HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 109 GERMANY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 110 U.K. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 111 U.K. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 112 U.K. DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 113 U.K. DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 114 U.K. DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 115 U.K. ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 116 U.K. IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 117 U.K. BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 118 U.K. BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 119 U.K. BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 120 U.K. DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 121 U.K. DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 122 U.K. CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 123 U.K. ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 124 U.K. ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 125 U.K. ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 126 U.K. ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 127 U.K. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 128 U.K. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 129 U.K. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 130 U.K. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 131 U.K. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 132 U.K. HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 133 U.K. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 134 FRANCE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 135 FRANCE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 136 FRANCE DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 137 FRANCE DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 138 FRANCE DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 139 FRANCE ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 140 FRANCE IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 141 FRANCE BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 142 FRANCE BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 143 FRANCE BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 144 FRANCE DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 145 FRANCE DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 146 FRANCE CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 147 FRANCE ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 148 FRANCE ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 149 FRANCE ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 150 FRANCE ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 151 FRANCE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 152 FRANCE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 153 FRANCE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 154 FRANCE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 155 FRANCE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 156 FRANCE HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 157 FRANCE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 158 ITALY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 159 ITALY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 160 ITALY DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 161 ITALY DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 162 ITALY DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 163 ITALY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 164 ITALY IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 165 ITALY BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 166 ITALY BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 167 ITALY BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 168 ITALY DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 169 ITALY DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 170 ITALY CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 171 ITALY ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 172 ITALY ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 173 ITALY ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 174 ITALY ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 175 ITALY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 176 ITALY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 177 ITALY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 178 ITALY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 179 ITALY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 180 ITALY HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 181 ITALY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 182 SPAIN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 183 SPAIN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 184 SPAIN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 185 SPAIN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 186 SPAIN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 187 SPAIN ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 188 SPAIN IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 189 SPAIN BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 190 SPAIN BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 191 SPAIN BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 192 SPAIN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 193 SPAIN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 194 SPAIN CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 195 SPAIN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 196 SPAIN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 197 SPAIN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 198 SPAIN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 199 SPAIN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 200 SPAIN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 201 SPAIN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 202 SPAIN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 203 SPAIN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 204 SPAIN HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 205 SPAIN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 206 TURKEY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 207 TURKEY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 208 TURKEY DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 209 TURKEY DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 210 TURKEY DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 211 TURKEY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 212 TURKEY IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 213 TURKEY BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 214 TURKEY BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 215 TURKEY BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 216 TURKEY DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 217 TURKEY DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 218 TURKEY CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 219 TURKEY ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 220 TURKEY ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 221 TURKEY ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 222 TURKEY ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 223 TURKEY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 224 TURKEY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 225 TURKEY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 226 TURKEY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 227 TURKEY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 228 TURKEY HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 229 TURKEY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 230 RUSSIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 231 RUSSIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 232 RUSSIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 233 RUSSIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 234 RUSSIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 235 RUSSIA ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 236 RUSSIA IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 237 RUSSIA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 238 RUSSIA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 239 RUSSIA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 240 RUSSIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 241 RUSSIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 242 RUSSIA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 243 RUSSIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 244 RUSSIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 245 RUSSIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 246 RUSSIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 247 RUSSIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 248 RUSSIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 249 RUSSIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 250 RUSSIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 251 RUSSIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 252 RUSSIA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 253 RUSSIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 254 SWITZERLAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 255 SWITZERLAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 256 SWITZERLAND DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 257 SWITZERLAND DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 258 SWITZERLAND DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 259 SWITZERLAND ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 260 SWITZERLAND IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 261 SWITZERLAND BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 262 SWITZERLAND BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 263 SWITZERLAND BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 264 SWITZERLAND DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 265 SWITZERLAND DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 266 SWITZERLAND CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 267 SWITZERLAND ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 268 SWITZERLAND ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 269 SWITZERLAND ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 270 SWITZERLAND ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 271 SWITZERLAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 272 SWITZERLAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 273 SWITZERLAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 274 SWITZERLAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 275 SWITZERLAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 276 SWITZERLAND HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 277 SWITZERLAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 278 NETHERLANDS POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 279 NETHERLANDS POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 280 NETHERLANDS DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 281 NETHERLANDS DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 282 NETHERLANDS DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 283 NETHERLANDS ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 284 NETHERLANDS IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 285 NETHERLANDS BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 286 NETHERLANDS BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 287 NETHERLANDS BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 288 NETHERLANDS DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 289 NETHERLANDS DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 290 NETHERLANDS CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 291 NETHERLANDS ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 292 NETHERLANDS ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 293 NETHERLANDS ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 294 NETHERLANDS ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 295 NETHERLANDS POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 296 NETHERLANDS POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 297 NETHERLANDS POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 298 NETHERLANDS POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 299 NETHERLANDS POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 300 NETHERLANDS HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 301 NETHERLANDS POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 302 BELGIUM POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 303 BELGIUM POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 304 BELGIUM DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 305 BELGIUM DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 306 BELGIUM DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 307 BELGIUM ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 308 BELGIUM IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 309 BELGIUM BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 310 BELGIUM BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 311 BELGIUM BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 312 BELGIUM DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 313 BELGIUM DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 314 BELGIUM CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 315 BELGIUM ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 316 BELGIUM ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 317 BELGIUM ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 318 BELGIUM ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 319 BELGIUM POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 320 BELGIUM POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 321 BELGIUM POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 322 BELGIUM POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 323 BELGIUM POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 324 BELGIUM HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 325 BELGIUM POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 326 AUSTRIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 327 AUSTRIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 328 AUSTRIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 329 AUSTRIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 330 AUSTRIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 331 AUSTRIA ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 332 AUSTRIA IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 333 AUSTRIA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 334 AUSTRIA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 335 AUSTRIA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 336 AUSTRIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 337 AUSTRIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 338 AUSTRIA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 339 AUSTRIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 340 AUSTRIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 341 AUSTRIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 342 AUSTRIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 343 AUSTRIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 344 AUSTRIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 345 AUSTRIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 346 AUSTRIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 347 AUSTRIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 348 AUSTRIA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 349 AUSTRIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 350 NORWAY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 351 NORWAY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 352 NORWAY DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 353 NORWAY DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 354 NORWAY DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 355 NORWAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 356 NORWAY IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 357 NORWAY BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 358 NORWAY BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 359 NORWAY BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 360 NORWAY DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 361 NORWAY DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 362 NORWAY CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 363 NORWAY ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 364 NORWAY ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 365 NORWAY ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 366 NORWAY ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 367 NORWAY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 368 NORWAY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 369 NORWAY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 370 NORWAY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 371 NORWAY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 372 NORWAY HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 373 NORWAY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 374 POLAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 375 POLAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 376 POLAND DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 377 POLAND DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 378 POLAND DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 379 POLAND ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 380 POLAND IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 381 POLAND BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 382 POLAND BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 383 POLAND BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 384 POLAND DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 385 POLAND DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 386 POLAND CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 387 POLAND ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 388 POLAND ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 389 POLAND ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 390 POLAND ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 391 POLAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 392 POLAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 393 POLAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 394 POLAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 395 POLAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 396 POLAND HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 397 POLAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 398 HUNGARY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 399 HUNGARY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 400 HUNGARY DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 401 HUNGARY DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 402 HUNGARY DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 403 HUNGARY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 404 HUNGARY IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 405 HUNGARY BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 406 HUNGARY BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 407 HUNGARY BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 408 HUNGARY DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 409 HUNGARY DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 410 HUNGARY CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 411 HUNGARY ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 412 HUNGARY ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 413 HUNGARY ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 414 HUNGARY ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 415 HUNGARY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 416 HUNGARY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 417 HUNGARY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 418 HUNGARY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 419 HUNGARY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 420 HUNGARY HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 421 HUNGARY POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 422 IRELAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 423 IRELAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 424 IRELAND DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 425 IRELAND DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 426 IRELAND DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 427 IRELAND ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 428 IRELAND IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 429 IRELAND BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 430 IRELAND BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 431 IRELAND BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 432 IRELAND DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 433 IRELAND DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 434 IRELAND CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 435 IRELAND ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 436 IRELAND ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 437 IRELAND ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 438 IRELAND ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 439 IRELAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 440 IRELAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 441 IRELAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 442 IRELAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 443 IRELAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 444 IRELAND HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 445 IRELAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 446 KAZAKHSTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 447 KAZAKHSTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 448 KAZAKHSTAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 449 KAZAKHSTAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 450 KAZAKHSTAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 451 KAZAKHSTAN ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 452 KAZAKHSTAN IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 453 KAZAKHSTAN BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 454 KAZAKHSTAN BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 455 KAZAKHSTAN BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 456 KAZAKHSTAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 457 KAZAKHSTAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 458 KAZAKHSTAN CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 459 KAZAKHSTAN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 460 KAZAKHSTAN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 461 KAZAKHSTAN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 462 KAZAKHSTAN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 463 KAZAKHSTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 464 KAZAKHSTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 465 KAZAKHSTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 466 KAZAKHSTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 467 KAZAKHSTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 468 KAZAKHSTAN HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 469 KAZAKHSTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 470 BELARUS POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 471 BELARUS POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 472 BELARUS DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 473 BELARUS DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 474 BELARUS DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 475 BELARUS ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 476 BELARUS IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 477 BELARUS BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 478 BELARUS BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 479 BELARUS BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 480 BELARUS DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 481 BELARUS DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 482 BELARUS CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 483 BELARUS ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 484 BELARUS ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 485 BELARUS ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 486 BELARUS ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 487 BELARUS POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 488 BELARUS POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 489 BELARUS POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 490 BELARUS POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 491 BELARUS POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 492 BELARUS HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 493 BELARUS POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 494 LITHUANIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 495 LITHUANIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 496 LITHUANIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 497 LITHUANIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 498 LITHUANIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 499 LITHUANIA ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 500 LITHUANIA IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 501 LITHUANIA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 502 LITHUANIA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 503 LITHUANIA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 504 LITHUANIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 505 LITHUANIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 506 LITHUANIA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 507 LITHUANIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 508 LITHUANIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 509 LITHUANIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 510 LITHUANIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 511 LITHUANIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 512 LITHUANIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 513 LITHUANIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 514 LITHUANIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 515 LITHUANIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 516 LITHUANIA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 517 LITHUANIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 518 UZBEKISTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 519 UZBEKISTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 520 UZBEKISTAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 521 UZBEKISTAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 522 UZBEKISTAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 523 UZBEKISTAN ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 524 UZBEKISTAN IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 525 UZBEKISTAN BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 526 UZBEKISTAN BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 527 UZBEKISTAN BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 528 UZBEKISTAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 529 UZBEKISTAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 530 UZBEKISTAN CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 531 UZBEKISTAN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 532 UZBEKISTAN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 533 UZBEKISTAN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 534 UZBEKISTAN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 535 UZBEKISTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 536 UZBEKISTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 537 UZBEKISTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 538 UZBEKISTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 539 UZBEKISTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 540 UZBEKISTAN HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 541 UZBEKISTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 542 AZERBAIJAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 543 AZERBAIJAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 544 AZERBAIJAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 545 AZERBAIJAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 546 AZERBAIJAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 547 AZERBAIJAN ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 548 AZERBAIJAN IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 549 AZERBAIJAN BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 550 AZERBAIJAN BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 551 AZERBAIJAN BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 552 AZERBAIJAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 553 AZERBAIJAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 554 AZERBAIJAN CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 555 AZERBAIJAN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 556 AZERBAIJAN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 557 AZERBAIJAN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 558 AZERBAIJAN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 559 AZERBAIJAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 560 AZERBAIJAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 561 AZERBAIJAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 562 AZERBAIJAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 563 AZERBAIJAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 564 AZERBAIJAN HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 565 AZERBAIJAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 566 ARMENIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 567 ARMENIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 568 ARMENIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 569 ARMENIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 570 ARMENIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 571 ARMENIA ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 572 ARMENIA IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 573 ARMENIA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 574 ARMENIA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 575 ARMENIA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 576 ARMENIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 577 ARMENIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 578 ARMENIA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 579 ARMENIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 580 ARMENIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 581 ARMENIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 582 ARMENIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 583 ARMENIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 584 ARMENIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 585 ARMENIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 586 ARMENIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 587 ARMENIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 588 ARMENIA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 589 ARMENIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 590 MOLDOVA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 591 MOLDOVA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 592 MOLDOVA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 593 MOLDOVA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 594 MOLDOVA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 595 MOLDOVA ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 596 MOLDOVA IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 597 MOLDOVA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 598 MOLDOVA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 599 MOLDOVA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 600 MOLDOVA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 601 MOLDOVA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 602 MOLDOVA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 603 MOLDOVA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 604 MOLDOVA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 605 MOLDOVA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 606 MOLDOVA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 607 MOLDOVA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 608 MOLDOVA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 609 MOLDOVA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 610 MOLDOVA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 611 MOLDOVA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 612 MOLDOVA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 613 MOLDOVA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 614 TAJIKISTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 615 TAJIKISTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 616 TAJIKISTAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 617 TAJIKISTAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 618 TAJIKISTAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 619 TAJIKISTAN ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 620 TAJIKISTAN IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 621 TAJIKISTAN BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 622 TAJIKISTAN BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 623 TAJIKISTAN BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 624 TAJIKISTAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 625 TAJIKISTAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 626 TAJIKISTAN CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 627 TAJIKISTAN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 628 TAJIKISTAN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 629 TAJIKISTAN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 630 TAJIKISTAN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 631 TAJIKISTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 632 TAJIKISTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 633 TAJIKISTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 634 TAJIKISTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 635 TAJIKISTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 636 TAJIKISTAN HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 637 TAJIKISTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 638 KYRGYZSTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 639 KYRGYZSTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 640 KYRGYZSTAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 641 KYRGYZSTAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 642 KYRGYZSTAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 643 KYRGYZSTAN ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 644 KYRGYZSTAN IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 645 KYRGYZSTAN BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 646 KYRGYZSTAN BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 647 KYRGYZSTAN BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 648 KYRGYZSTAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 649 KYRGYZSTAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 650 KYRGYZSTAN CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 651 KYRGYZSTAN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 652 KYRGYZSTAN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 653 KYRGYZSTAN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 654 KYRGYZSTAN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 655 KYRGYZSTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 656 KYRGYZSTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 657 KYRGYZSTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 658 KYRGYZSTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 659 KYRGYZSTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 660 KYRGYZSTAN HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 661 KYRGYZSTAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 662 REST OF EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
List of Figure
FIGURE 1 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: SEGMENTATION
FIGURE 2 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: DROC ANALYSIS
FIGURE 4 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: END USER COVERAGE GRID
FIGURE 8 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: SEGMENTATION
FIGURE 11 TEN SEGMENTS COMPRISE THE EUROPE POINT-OF-CARE DRUG ABUSE TESTING MARKET, BY DRUG TYPE
FIGURE 12 EXECUTIVE SUMMARY
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 RISING INCIDENCE OF DRUG ABUSE IS DRIVING THE GROWTH OF THE EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET FROM 2024 TO 2031
FIGURE 15 THE AMPHETAMINES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOB POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET IN 2024 AND 2031
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET
FIGURE 17 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DRUG TYPE, 2023
FIGURE 18 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND)
FIGURE 19 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 20 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 21 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRODUCTS 2023
FIGURE 22 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRODUCTS, 2024-2031 (USD THOUSAND)
FIGURE 23 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRODUCTS, CAGR (2024-2031)
FIGURE 24 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRODUCTS, LIFELINE CURVE
FIGURE 25 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRESCRIPTION, 2023
FIGURE 26 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRESCRIPTION, 2024-2031 (USD THOUSAND)
FIGURE 27 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRESCRIPTION, CAGR (2024-2031)
FIGURE 28 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRESCRIPTION, LIFELINE CURVE
FIGURE 29 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY SAMPLE TYPE, 2023
FIGURE 30 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY SAMPLE TYPE, 2024-2031 (USD THOUSAND)
FIGURE 31 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY SAMPLE TYPE, CAGR (2024-2031)
FIGURE 32 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY SAMPLE TYPE, LIFELINE CURVE
FIGURE 33 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY TESTING TYPE, 2023
FIGURE 34 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY TESTING TYPE, 2024-2031 (USD THOUSAND)
FIGURE 35 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY TESTING TYPE, CAGR (2024-2031)
FIGURE 36 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET : BY TESTING TYPE, LIFELINE CURVE
FIGURE 37 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY APPLICATION, 2023
FIGURE 38 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY APPLICATION, 2024-2031 (USD THOUSAND)
FIGURE 39 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY APPLICATION, CAGR (2024-2031)
FIGURE 40 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 41 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY END USER, 2023
FIGURE 42 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 43 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY END USER, CAGR (2024-2031)
FIGURE 44 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY END USER, LIFELINE CURVE
FIGURE 45 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 46 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)
FIGURE 47 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 48 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 49 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: SNAPSHOT (2023)
FIGURE 50 EUROPE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: COMPANY SHARE 2023 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
